230 related articles for article (PubMed ID: 30566230)
1. Population Pharmacokinetics and Exposure-Response Analyses for CPX-351 in Patients With Hematologic Malignancies.
Wang Q; Banerjee K; Vasilinin G; Marier JF; Gibbons JA
J Clin Pharmacol; 2019 May; 59(5):748-762. PubMed ID: 30566230
[TBL] [Abstract][Full Text] [Related]
2. Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment.
Nikanjam M; Capparelli EV; Lancet JE; Louie A; Schiller G
Cancer Chemother Pharmacol; 2018 Jan; 81(1):171-178. PubMed ID: 29167924
[TBL] [Abstract][Full Text] [Related]
3. A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias.
Lin TL; Newell LF; Stuart RK; Michaelis LC; Rubenstein E; Pentikis HS; Callahan T; Alvarez D; Liboiron BD; Mayer LD; Wang Q; Banerjee K; Louie AC
Cancer Chemother Pharmacol; 2019 Jul; 84(1):163-173. PubMed ID: 31098682
[TBL] [Abstract][Full Text] [Related]
4. CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia.
Cafaro A; Giannini MB; Silimbani P; Cangini D; Masini C; Ghelli Luserna Di Rorà A; Simonetti G; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):455-466. PubMed ID: 32955826
[TBL] [Abstract][Full Text] [Related]
5. CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties.
Mayer LD; Tardi P; Louie AC
Int J Nanomedicine; 2019; 14():3819-3830. PubMed ID: 31213803
[TBL] [Abstract][Full Text] [Related]
6. Daunorubicin and Cytarabine Liposome in Newly Diagnosed Therapy-Related Acute Myeloid Leukemia (AML) or AML With Myelodysplasia-Related Changes.
Kim M; Williams S
Ann Pharmacother; 2018 Aug; 52(8):792-800. PubMed ID: 29532662
[TBL] [Abstract][Full Text] [Related]
7. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.
Feldman EJ; Lancet JE; Kolitz JE; Ritchie EK; Roboz GJ; List AF; Allen SL; Asatiani E; Mayer LD; Swenson C; Louie AC
J Clin Oncol; 2011 Mar; 29(8):979-85. PubMed ID: 21282541
[TBL] [Abstract][Full Text] [Related]
8. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
Lancet JE; Uy GL; Cortes JE; Newell LF; Lin TL; Ritchie EK; Stuart RK; Strickland SA; Hogge D; Solomon SR; Stone RM; Bixby DL; Kolitz JE; Schiller GJ; Wieduwilt MJ; Ryan DH; Hoering A; Banerjee K; Chiarella M; Louie AC; Medeiros BC
J Clin Oncol; 2018 Sep; 36(26):2684-2692. PubMed ID: 30024784
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program.
Carol H; Fan MM; Harasym TO; Boehm I; Mayer LD; Houghton P; Smith MA; Lock RB
Pediatr Blood Cancer; 2015 Jan; 62(1):65-71. PubMed ID: 25203866
[TBL] [Abstract][Full Text] [Related]
10. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial.
Lancet JE; Uy GL; Newell LF; Lin TL; Ritchie EK; Stuart RK; Strickland SA; Hogge D; Solomon SR; Bixby DL; Kolitz JE; Schiller GJ; Wieduwilt MJ; Ryan DH; Faderl S; Cortes JE
Lancet Haematol; 2021 Jul; 8(7):e481-e491. PubMed ID: 34171279
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.
Lancet JE; Cortes JE; Hogge DE; Tallman MS; Kovacsovics TJ; Damon LE; Komrokji R; Solomon SR; Kolitz JE; Cooper M; Yeager AM; Louie AC; Feldman EJ
Blood; 2014 May; 123(21):3239-46. PubMed ID: 24687088
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, drug metabolism, and tissue distribution of CPX-351 in animals.
Wang Q; Tardi P; Sadowski N; Xie S; Heller D; Mayer L
Nanomedicine; 2020 Nov; 30():102275. PubMed ID: 32750494
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia.
Feldman EJ; Kolitz JE; Trang JM; Liboiron BD; Swenson CE; Chiarella MT; Mayer LD; Louie AC; Lancet JE
Leuk Res; 2012 Oct; 36(10):1283-9. PubMed ID: 22840315
[TBL] [Abstract][Full Text] [Related]
14. Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML.
Cortes JE; Lin TL; Uy GL; Ryan RJ; Faderl S; Lancet JE
J Hematol Oncol; 2021 Jul; 14(1):110. PubMed ID: 34256819
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of CPX-351 (cytarabine/daunorubicin HCl) liposome injection in the mouse.
Bayne WF; Mayer LD; Swenson CE
J Pharm Sci; 2009 Jul; 98(7):2540-8. PubMed ID: 19009594
[TBL] [Abstract][Full Text] [Related]
16. Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.
Cortes JE; Goldberg SL; Feldman EJ; Rizzeri DA; Hogge DE; Larson M; Pigneux A; Recher C; Schiller G; Warzocha K; Kantarjian H; Louie AC; Kolitz JE
Cancer; 2015 Jan; 121(2):234-42. PubMed ID: 25223583
[TBL] [Abstract][Full Text] [Related]
17. Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts.
Lim WS; Tardi PG; Dos Santos N; Xie X; Fan M; Liboiron BD; Huang X; Harasym TO; Bermudes D; Mayer LD
Leuk Res; 2010 Sep; 34(9):1214-23. PubMed ID: 20138667
[TBL] [Abstract][Full Text] [Related]
18. Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study.
van Eijkelenburg NKA; Rasche M; Ghazaly E; Dworzak MN; Klingebiel T; Rossig C; Leverger G; Stary J; De Bont ESJM; Chitu DA; Bertrand Y; Brethon B; Strahm B; van der Sluis IM; Kaspers GJL; Reinhardt D; Zwaan CM
Haematologica; 2018 Sep; 103(9):1484-1492. PubMed ID: 29773602
[TBL] [Abstract][Full Text] [Related]
19. Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia.
Blair HA
Drugs; 2018 Dec; 78(18):1903-1910. PubMed ID: 30511323
[TBL] [Abstract][Full Text] [Related]
20. FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia.
Krauss AC; Gao X; Li L; Manning ML; Patel P; Fu W; Janoria KG; Gieser G; Bateman DA; Przepiorka D; Shen YL; Shord SS; Sheth CM; Banerjee A; Liu J; Goldberg KB; Farrell AT; Blumenthal GM; Pazdur R
Clin Cancer Res; 2019 May; 25(9):2685-2690. PubMed ID: 30541745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]